Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
ProteinQure logo — dare to deliver

ProteinQure

dare to deliver

Founded 2017 Canada Toronto, Canada 33 employees Series A Total: $18.12M Biotechnology

General Information

Company Name ProteinQure
Founded Year 2017
Location Canada Toronto, Canada
Founders / Decision Makers
Team member
Employees 33
Industries Biotechnology
Funding Stage Series A
Business Model B2B, Platform, SaaS
Revenue Model Performance Based, Licensing, Project Based
Social

BounceWatch is an independent company data service, not affiliated with ProteinQure. To contact ProteinQure, visit proteinqure.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does ProteinQure compare?

A PDF of ProteinQure and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting ProteinQure soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Grant Received Oct 14, 2026

ProteinQure's project OpenPep received $2.3M USD from the Google.org Impact Challenge: AI for Science.

Feature Release Oct 09, 2026

ProteinQure launched v1.1 of its open-source peptide monomer database, expanding to nearly 5,000 monomers with new search and sourcing tools.

ProteinQure a competitor of yours? Have our desk watch it

About ProteinQure

ProteinQure, founded in 2017 and headquartered in Canada, is at the forefront of biotechnology. Armed with the slogan "dare to deliver," the company is pioneering an AI platform designed for peptide drug design, particularly targeting extracellular targets.

Their flagship program, PQ203, is currently undergoing Phase I trials in the U.S. and Canada, addressing TOP1-resistant triple-negative breast cancer, a condition that currently lacks approved treatments. This marks a significant milestone in therapeutic advancement.

ProteinQure's platform has been rigorously validated through collaborations with four of the world's top 25 pharmaceutical companies. It leverages cutting-edge physics-based methods to explore an extensive chemical space, boasting scaffold diversity and over 3,500 non-canonical building blocks.

Recently, the company secured a $1.80M grant investment from FedDev on 01 May 2026, showcasing confidence in ProteinQure's potential. This investment bolsters their internal programs, specifically those enhancing tissue-specific payload delivery.

Business keywords: AI platform for drug design, peptide drug design, extracellular targets, TOP1-resistant breast cancer, Phase I clinical trials, pharmaceutical collaborations, proprietary physics-based methods, chemical space exploration, scaffold diversity, non-canonical building blocks, tissue-specific payload delivery, siRNA delivery, central nervous system therapies

Services & Products

Development of AI-designed peptide-drug conjugates
Precision drug delivery solutions
Proprietary computational platform (ProteinStudio) for peptide design
Clinical trials for peptide-based therapeutics
Research and development in oncology solutions

Target Customers

Pharmaceutical companies Biotech researchers Clinical oncology specialists Medical research institutions Patients with advanced solid tumors

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Grant $1.80M 1
FedDev
FedDev
01 May 2026
Series A $11.00M 3
Golden Ventures Kensington Capital Partners
Golden Ventures, Kensington Capital Partners +1
01 May 2025
Debt Financing $700.00K 1
Government of Canada
Government of Canada
01 Feb 2024
Seed $4.00M 5
Felicis Ventures 8VC Global Founders Capital
Felicis Ventures, 8VC +3
01 Jul 2019
Seed $540.00K -
01 Jul 2018
Spinout $80.00K 1
Google
Google
01 Dec 2017

ProteinQure Alternatives & Competitors

View All Alternatives
ProteinQure vs
Perpetual Medicines
Perpetual Medicines

AI-powered computational platform for peptide drug discovery

Acquired
2 employees
Biotechnology
ProteinQure vs
Menten AI
Menten AI United States

Unlocking the potential of peptides macrocycles to create tomorrow's life-changing medicines with Ge...

Seed
19 employees
AI, Biotechnology
ProteinQure vs
Manifold Bio
Manifold Bio United States

Organism-scale intelligence, designed in vivo

Series A
81 employees
Biotechnology, Health Care
View all alternatives

FAQ About ProteinQure

dare to deliver
ProteinQure was founded in 2017.
ProteinQure is headquartered in Toronto, Canada.
ProteinQure operates in Biotechnology. Its work centres on AI platform for drug design, peptide drug design, extracellular targets and TOP1-resistant breast cancer. Its customers include Pharmaceutical companies, Biotech researchers and Clinical oncology specialists.
ProteinQure has a B2B, Platform and SaaS business model. Its revenue comes from Performance Based, Licensing and Project Based.
ProteinQure has approximately 33 employees.
ProteinQure has completed 6 funding rounds, raising a total of $18.12M. The latest funding stage is Series A.
ProteinQure offers: Development of AI-designed peptide-drug conjugates, Precision drug delivery solutions, Proprietary computational platform (ProteinStudio) for peptide design, Clinical trials for peptide-based therapeutics, Research and development in oncology solutions.
Top alternatives and competitors to ProteinQure include Perpetual Medicines, Menten AI, Manifold Bio, Aro Biotherapeutics, Cybrexa Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ProteinQure and Perpetual Medicines are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for ProteinQure, https://bouncewatch.com/company/proteinqure, updated 6 November 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout